(DOCS) Doximity - Ratings and Ratios
Digital Tools, Medical News, Career Management, Virtual Visits, Administrative
DOCS EPS (Earnings per Share)
DOCS Revenue
Description: DOCS Doximity
Doximity, Inc. (NYSE:DOCS) is a digital platform catering to medical professionals in the United States, providing a suite of tools that facilitate collaboration, staying updated on medical news and research, career management, and streamlining administrative tasks. The platform serves a broad user base including physicians, nurse practitioners, and medical students, as well as pharmaceutical manufacturers and healthcare systems.
From a business perspective, Doximitys model is centered around creating a professional network for healthcare providers, enhancing their ability to manage their careers and practices efficiently. Key Performance Indicators (KPIs) that could be crucial in evaluating the companys performance include user growth rate, revenue per user, and the percentage of revenue derived from different segments such as pharmaceutical manufacturers and healthcare systems. The companys ability to maintain a strong user engagement is also vital, as it directly impacts the platforms value proposition for its clients.
Given its position in the Health Care Technology sub-industry, Doximitys growth and profitability are influenced by trends in healthcare digitization, telemedicine adoption, and the overall demand for streamlined clinical workflows. The companys financial health, as indicated by metrics like Market Cap ($11.3B) and Return on Equity (22.38%), suggests a significant presence in the market. The Price-to-Earnings ratio (55.45) and Forward P/E (44.64) imply expectations of future growth, although the high P/E ratio may also suggest that the stock is currently priced at a premium.
To further analyze Doximitys potential, its essential to monitor its ability to innovate and expand its service offerings, its competitive positioning against other healthcare technology platforms, and its capacity to navigate regulatory changes in the healthcare sector. The companys growth trajectory, user adoption rates, and the overall stickiness of its platform will be critical in determining its long-term success and, by extension, the stocks performance.
DOCS Stock Overview
| Market Cap in USD | 13,160m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2021-06-24 |
DOCS Stock Ratings
| Growth Rating | 63.8% |
| Fundamental | 89.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 54.6% |
| Analyst Rating | 3.68 of 5 |
DOCS Dividends
Currently no dividends paidDOCS Growth Ratios
| Growth Correlation 3m | 79% |
| Growth Correlation 12m | 67.1% |
| Growth Correlation 5y | -4.6% |
| CAGR 5y | 32.84% |
| CAGR/Max DD 3y | 0.66 |
| CAGR/Mean DD 3y | 1.45 |
| Sharpe Ratio 12m | 1.00 |
| Alpha | 87.21 |
| Beta | 0.325 |
| Volatility | 42.26% |
| Current Volume | 1665.6k |
| Average Volume 20d | 1165.3k |
| Stop Loss | 70.2 (-3.1%) |
| Signal | 0.81 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (235.1m TTM) > 0 and > 6% of Revenue (6% = 35.4m TTM) |
| FCFTA 0.24 (>2.0%) and ΔFCFTA 8.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 148.3% (prev 156.6%; Δ -8.35pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 294.1m > Net Income 235.1m (YES >=105%, WARN >=100%) |
| Net Debt (-125.4m) to EBITDA (259.1m) ratio: -0.48 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (201.2m) change vs 12m ago 0.97% (target <= -2.0% for YES) |
| Gross Margin 90.14% (prev 89.65%; Δ 0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.77% (prev 45.98%; Δ 5.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 7.24
| (A) 0.73 = (Total Current Assets 1.03b - Total Current Liabilities 159.9m) / Total Assets 1.20b |
| (B) 0.10 = Retained Earnings (Balance) 117.1m / Total Assets 1.20b |
| (C) 0.22 = EBIT TTM 248.2m / Avg Total Assets 1.14b |
| (D) 0.66 = Book Value of Equity 118.5m / Total Liabilities 178.9m |
| Total Rating: 7.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.28
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.34% = 1.17 |
| 3. FCF Margin 49.06% = 7.50 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.09 = 2.49 |
| 6. ROIC - WACC 13.28% = 12.50 |
| 7. RoE 22.94% = 1.91 |
| 8. Rev. Trend 85.39% = 4.27 |
| 9. Rev. CAGR 13.83% = 1.73 |
| 10. EPS Trend 88.03% = 2.20 |
| 11. EPS CAGR 32.24% = 2.50 |
What is the price of DOCS shares?
Over the past week, the price has changed by +4.24%, over one month by +11.27%, over three months by +29.50% and over the past year by +83.75%.
Is Doximity a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DOCS is around 72.47 USD . This means that DOCS is currently overvalued and has a potential downside of 0%.
Is DOCS a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DOCS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.2 | -5.9% |
| Analysts Target Price | 68.2 | -5.9% |
| ValueRay Target Price | 79.9 | 10.2% |
Last update: 2025-09-13 05:02
DOCS Fundamental Data Overview
CCE Cash And Equivalents = 841.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 60.0513
P/E Forward = 46.5116
P/S = 22.3182
P/B = 12.8312
P/EG = 2.4191
Beta = 1.371
Revenue TTM = 589.6m USD
EBIT TTM = 248.2m USD
EBITDA TTM = 259.1m USD
Long Term Debt = 18.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.34m USD (from shortTermDebt, last quarter)
Debt = 23.3m USD (Calculated: Short Term 4.34m + Long Term 18.9m)
Net Debt = -125.4m USD (from netDebt column, last quarter)
Enterprise Value = 12.34b USD (13.16b + Debt 23.3m - CCE 841.0m)
Interest Coverage Ratio = unknown (Ebit TTM 248.2m / Interest Expense TTM 0.0)
FCF Yield = 2.34% (FCF TTM 289.3m / Enterprise Value 12.34b)
FCF Margin = 49.06% (FCF TTM 289.3m / Revenue TTM 589.6m)
Net Margin = 39.88% (Net Income TTM 235.1m / Revenue TTM 589.6m)
Gross Margin = 90.14% ((Revenue TTM 589.6m - Cost of Revenue TTM 58.1m) / Revenue TTM)
Tobins Q-Ratio = 104.2 (set to none) (Enterprise Value 12.34b / Book Value Of Equity 118.5m)
Interest Expense / Debt = 16.65% (Interest Expense 3.88m / Debt 23.3m)
Taxrate = 15.32% (40.4m / 263.6m)
NOPAT = 210.2m (EBIT 248.2m * (1 - 15.32%))
Current Ratio = 6.47 (Total Current Assets 1.03b / Total Current Liabilities 159.9m)
Debt / Equity = 0.02 (Debt 23.3m / last Quarter total Stockholder Equity 1.03b)
Debt / EBITDA = 0.09 (Net Debt -125.4m / EBITDA 259.1m)
Debt / FCF = 0.08 (Debt 23.3m / FCF TTM 289.3m)
Total Stockholder Equity = 1.03b (last 4 quarters mean)
RoA = 19.52% (Net Income 235.1m, Total Assets 1.20b )
RoE = 22.94% (Net Income TTM 235.1m / Total Stockholder Equity 1.03b)
RoCE = 23.77% (Ebit 248.2m / (Equity 1.03b + L.T.Debt 18.9m))
RoIC = 20.50% (NOPAT 210.2m / Invested Capital 1.03b)
WACC = 7.22% (E(13.16b)/V(13.18b) * Re(7.21%)) + (D(23.3m)/V(13.18b) * Rd(16.65%) * (1-Tc(0.15)))
Shares Correlation 3-Years: -48.48 | Cagr: -0.56%
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈238.5m ; Y1≈294.2m ; Y5≈501.9m
Fair Price DCF = 62.59 (DCF Value 8.54b / Shares Outstanding 136.4m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 85.39 | Revenue CAGR: 13.83%
Rev Growth-of-Growth: 3.52
EPS Correlation: 88.03 | EPS CAGR: 32.24%
EPS Growth-of-Growth: 3.68
Additional Sources for DOCS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle